Recurrent epithelial ovarian cancer: an update on treatment.
about
Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-AnalysisChemoresistance and targeted therapies in ovarian and endometrial cancersStereotactic radiosurgery for brain metastasis from gynecological malignanciesPlasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer.Prognostic roles of Notch receptor mRNA expression in human ovarian cancer.MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.Changing trends in the incidence of ovarian neoplasia and its relationship with the risk factors: a report of 311 cases from north-eastern anatolia region.Expression of BAF57 in ovarian cancer cells and drug sensitivity.A 10-gene expression signature of Notch pathway predicts recurrence in ovarian carcinomaDynamic changes of tumor gene expression during repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with peritoneal cancer.Comprehensive discovery of subsample gene expression components by information explanation: therapeutic implications in cancer.Correlation analysis of urine metabolites and clinical staging in patients with ovarian cancer.Prognostic values of aldehyde dehydrogenase 1 isoenzymes in ovarian cancer.HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cellsPreclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.The role and expression of miR-100 and miR-203 profile as prognostic markers in epithelial ovarian cancer.Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.TGFβ Controls Ovarian Cancer Cell ProliferationDisulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition.Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature.Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.Advances in ovarian cancer therapy.Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada.Prognostic values of aquaporins mRNA expression in human ovarian cancer.The expression of asparaginyl endopeptidase promotes growth potential in epithelial ovarian cancer.Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment.Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials
P2860
Q26785421-B9890B5E-D1D2-45FC-B07C-17309DE2443DQ28073246-6D5C345A-9723-42CC-8D2F-7C7A4B4E1B17Q33598798-5D49D5E2-17FE-45FB-A3F7-8DB43A001473Q33660646-6A16BD8B-7C4A-4B77-ADCB-5AAE8BDDA1FCQ33779227-4CD254A6-6BFA-4C5C-A495-1C542FB7F32AQ33999853-CAEE2D0F-AF2F-4F62-9F46-514C9BF88805Q34022694-D01BEDD9-259B-43C8-977B-6CB6783B89EDQ34541689-25BB0945-002D-4A4A-984C-EED3F3956623Q35124883-C6E4F27B-71F1-4C62-BA1E-D0CBEEF601A1Q35538429-2BA1544E-2AC1-41B2-8391-18738A213225Q35944512-F57C52C2-966B-4B80-8DCF-A135E150C974Q36108028-26F6FA17-035B-464C-B9F6-483294941E5FQ36307837-955C6959-7EC3-4E8E-89B8-DF909539680AQ36411755-C980A981-859F-4F3F-B3C5-8196366B7DCBQ36798021-196757E4-544A-49DC-8CC8-318515688BEBQ36907257-47C22C58-1521-4E42-81ED-FDB456556647Q36962480-D7200FC5-4DE0-4779-A873-B583A9035C73Q36964202-368393E0-F995-4E99-879F-94DB6BF7F831Q37683243-0E83ED2C-2061-4053-BD5E-26863B66AE7FQ38774676-65A39495-C0D5-4D8F-AA45-960F01C5EE3DQ41573289-E66095E8-C6C7-49E2-988A-A0CF8AC1CA94Q41575123-4E9D2A7E-47FF-408E-9C8A-C76783436A35Q41619260-957E7F43-B281-4955-889B-C0CC9F6253A9Q43203991-B28B4790-6C9E-4FB0-9EAE-C75671CE940DQ46085386-3C7CDFC9-56CF-48B0-9D21-DA4CEBDCD12BQ47955849-F3A3AF56-A08E-4FDB-99DC-A1655B275044Q48104995-0E726025-BA5D-488B-AD4C-74E3E2C9E780Q49720607-3599DA03-9847-40B0-B147-B7BA05732A48Q52689241-63E31DE9-3620-486A-B618-1799BE1EE10EQ53449580-DECA00FD-70FF-4479-AF0F-7AB8AD9B9D14Q55265735-443DF70B-46A0-43B7-B5CA-65C7BC695DE9Q57074340-3798E029-6F78-458C-A6CD-A301827C5C77
P2860
Recurrent epithelial ovarian cancer: an update on treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recurrent epithelial ovarian cancer: an update on treatment.
@en
type
label
Recurrent epithelial ovarian cancer: an update on treatment.
@en
prefLabel
Recurrent epithelial ovarian cancer: an update on treatment.
@en
P2093
P1433
P1476
Recurrent epithelial ovarian cancer: an update on treatment.
@en
P2093
J Alejandro Rauh-Hain
Marcela G del Carmen
Olivia W Foley
P304
288-94, 298
P577
2013-04-01T00:00:00Z